The firm said that it is the first point-of-care diagnostic test available in the US to detect a potentially fatal disease that affects around 8 million people globally.
The funding will be used to further develop a 20-minute tuberculosis detection assay and drug susceptibility test using the firm's handheld Q-POC microfluidic PCR system.
The firm said that the system is unique because it consists of cell, immunoassay, and nucleic acid tests within one platform.
The company said this week that is has raised $36 million in funding, as it continues efforts to develop its Maverick platform for rapid testing in doctors' offices.
The firm is building an antibody-based immune system-related protein biomarker test for stroke diagnosis in both community and academic hospitals.
The test is the first in a proposed line of assays that will run on the GeneXpress platform with run times of around 30 minutes.
For the 40-target panel, the trial found an overall average weighted sensitivity and specificity of 90 and 99 percent, respectively.
The Chinese firm is also developing a menu of extraction-free molecular diagnostic tests using a proprietary "one-step" reagent.
CEO Miles White said that he still believes that Alere is a good strategic fit for Abbott, and the firm is pursuing all of the necessary regulatory approvals for the deal.
The portable system uses centrifugal microfluidics, with molecular tests deploying a visualization method that obviates the need for sample prep.
The device, which will be tested in collaboration with a Panamanian research institute, will run 40-minute tests without the need for electricity.
The company has built a small and rugged system boasting 20-minute qPCR reactions and plans to expand the platform for other types of diagnostics.
The Alere flu test detected fewer cases of influenza A in a recent study, which researchers attributed to low viral loads.
The point-of-care test delivers results in 13 minutes or less and will be available for the 2016-2017 respiratory season.
Facing CMS sanctions, lab industry insiders ponder the firm's options in seeking to launch a Zika virus assay with emergency use authorization on its upcoming miniLab platform.
The UK-based engineering consultancy has developed a small, lightweight platform that can run PCR assays in 7 seconds per cycle.
At the American Association for Clinical Chemistry meeting, Theranos CEO Elizabeth Holmes said her company is working on third-party review and publications of the firm's technologies and tests.
The point-of-care test detects and distinguishes influenza A and B as well as respiratory syncytial virus in about 20 minutes.
The firm launched the multiplex PCR-based test this week on its Spartan Cube platform to support patient enrollment in Alzheimer's clinical trials.
Abbott's MDx sales were driven by continued strong growth in its infectious disease testing business but were partly offset by the planned scale down of its genetics business.